Holen Sie sich die Stockscreener-App
351.97
0.83%
2.9747
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$349.00
Offen:
$350.73
24-Stunden-Volumen:
1.62M
Relative Volume:
0.61
Marktkapitalisierung:
$190.09B
Einnahmen:
$36.74B
Nettoeinkommen (Verlust:
$7.71B
KGV:
24.73
EPS:
14.2333
Netto-Cashflow:
$8.10B
1W Leistung:
+1.00%
1M Leistung:
-9.34%
6M Leistung:
+24.70%
1J Leistung:
+12.95%
1-Tages-Spanne:
$347.11
$355.49
1-Wochen-Bereich:
$347.11
$358.00
52-Wochen-Spanne:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
352.62 | 188.13B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
920.31 | 792.08B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.25 | 584.06B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
217.69 | 376.96B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
196.19 | 300.68B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.13 | 291.99B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Hold |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-20 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
FDA Says Amgen’s Tavneos Linked to Liver Injuries, Deaths - WSJ
US FDA warns of liver injury cases tied to Amgen's rare disease drug - Reuters
FDA Flags Serious Liver Risks with Amgen's Tavneos (AMGN) - GuruFocus
FDA issues warning for Amgen's Tavneos following serious liver injury cases - Seeking Alpha
Amgen CEO Bob Bradway's 2025 Letter to Shareholders - Amgen
Amgen’s Tavneos Associated With Liver Injury, Deaths, FDA Says - Bloomberg.com
Amgen price breaches upside trend lineForecast tody31-03-2026 - Economies.com
Amgen Inc. $AMGN Shares Purchased by Hofer & Associates. Inc - MarketBeat
The Zacks Analyst Blog Roche Holding, AT&T and Amgen - theglobeandmail.com
Mn Services Vermogensbeheer B.V. Acquires 3,327 Shares of Amgen Inc. $AMGN - MarketBeat
Financial Planning Hawaii Inc. Takes Position in Amgen Inc. $AMGN - MarketBeat
Brookstone Capital Management Purchases 3,098 Shares of Amgen Inc. $AMGN - MarketBeat
Top Stock Reports for Roche, AT&T & Amgen - The Globe and Mail
Jefferies reiterates Amgen stock Hold rating on TED trial data - Investing.com
Amgen Inc. Stock: Steady Biotech Leader with Strong Dividend Yield and Growth Guidance Amid Analyst - AD HOC NEWS
Amgen’s Repatha Slashes Heart Event Risk in Early‑Stage Patients - Citeline News & Insights
Teva gagne du terrain dans le domaine des médicaments biosimilaires grâce à l’approbation accordée par la FDA pour PONLIMSI™ (dénosumab-adet) et à l’acceptation d’un double dossier pour un candidat biosimilaire à Xolair® (omalizumab) - GlobeNewswire Inc.
Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen” - Insider Monkey
R.H. Dinel Investment Counsel Inc. Has $6.33 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Exchange Traded Concepts LLC Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
Here's What You Need to Know about Amgen, Inc's AMG-145 - Yahoo
Amgen Inc. $AMGN Shares Bought by Wealthcare Advisory Partners LLC - MarketBeat
Nova R Wealth Inc. Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen’s Repatha Data Reinforces Cardiovascular Franchise And Valuation Debate - simplywall.st
Amgen's Repatha Cuts Risk Of First Major Cardiovascular Event By 31% In High-Risk Patients - TradingView
In diabetes patients, Repatha cut first major heart event risk 31% - Stock Titan
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here is what to know beyond why Amgen Inc. (AMGN) is a trending stock - MSN
Anti-Cancer MAbS Market Report 2026-2030 Featuring - GlobeNewswire
Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players - Yahoo Finance
Amgen stock consolidates as leaders tout AI in medicine discovery and delivery - Traders Union
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock - Yahoo Finance
Global X Japan Co. Ltd. Has $6.80 Million Position in Amgen Inc. $AMGN - MarketBeat
Dakota Wealth Management Acquires 4,581 Shares of Amgen Inc. $AMGN - MarketBeat
Assessing Amgen (AMGN) Valuation As Shares Show Mixed Short And Long Term Returns - simplywall.st
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Amgen stock moves lower after Rep Luz Rivas joins Amgen Foundation students - Traders Union
Vanguard Group reports zero Amgen (AMGN) holdings after internal realignment - Stock Titan
Amgen Inc. Stock: Steady Biotech Leader with Strong Dividend Yield and Institutional Backing for Nor - AD HOC NEWS
National Wealth Management Group LLC Makes New $1.53 Million Investment in Amgen Inc. $AMGN - MarketBeat
FY2027 EPS Estimates for Amgen Increased by Erste Group Bank - MarketBeat
Ferguson Wellman Capital Management Inc. Has $102.76 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Czech National Bank - MarketBeat
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Amgen Named One of the 2026 World’s Most Ethical Companies® by Ethisphere - Amgen
Amgen Named One of the World’s Most Ethical Companies® by Ethisphere - Amgen
Amgen’s Rocatinlimab Trial Completion Signals Next Phase for Atopic Dermatitis Strategy - TipRanks
Wells Fargo raises its price target on Amgen (AMGN) to $390 from $375 - MSN
Wells Fargo Raises its Price Target on Amgen (AMGN) to $390 from $375 - Insider Monkey
Pensionfund Sabic Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amgen Inc-Aktie (AMGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):